- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Zinc peroxide-based nanotheranostic platform with endogenous hydrogen peroxide/oxygen generation for enhanced photodynamic-chemo therapy of tumors. (Pubmed Central) - May 12, 2024
DOX/ZnO2@Zr-Ce6/Pt/PEG nanocomposite was prepared by the synthesis of ZnO2 nanoparticles, in-situ assembly of Zr-Ce6 as typical metal-organic framework (MOF) on ZnO2 surface, in-situ reduction of Pt nanozymes, amphiphilic lipids surface coating and then doxorubicin (DOX) loading...The photodynamic-chemo combination therapy from DOX/ZnO2@Zr-Ce6/Pt/PEG nanoplatform exhibits remarkable tumor growth inhibition compared to chemotherapy or PDT. Thus, the present study is a good demonstration of a TME-responsive nanoplatform in a multimodal approach for cancer therapy.
- |||||||||| doxorubicin hydrochloride / Generic mfg., celecoxib oral / Generic mfg.
Journal: Exploration of isoxazole analogs: Synthesis, COX inhibition, anticancer screening, 3D multicellular tumor spheroids, and molecular modeling. (Pubmed Central) - May 11, 2024
Thus, the present study is a good demonstration of a TME-responsive nanoplatform in a multimodal approach for cancer therapy. Intriguingly, this compound displayed significant antiproliferative effects against CaCo-2, Hep3B, and HeLa cancer cell lines, with IC50 values of 10.22, 4.84, and 1.57
- |||||||||| pevonedistat (MLN4924) / Takeda
Preclinical, Journal: The NEDD8 activating enzyme inhibitor MLN4924 mitigates doxorubicin-induced cardiotoxicity in mice. (Pubmed Central) - May 11, 2024
Among these, the development of cardiomyopathy, characterized by cardiac remodeling and eventual heart failure, stands as a major concern following Dox chemotherapy.In our current investigation, we have showcased the efficacy of MLN4924 in mitigating doxorubicin-induced cardiotoxicity through direct inhibition of the NEDD8-activating enzyme, NAE.MLN4924 demonstrated the ability to stabilize mitochondrial function post-doxorubicin treatment, diminish cardiomyocyte apoptosis, alleviate oxidative stress-induced damage in the myocardium, enhance cardiac contractile function, mitigate cardiac fibrosis, and impede cardiac remodeling associated with heart failure. At the mechanistic level, MLN4924 intervened in the neddylation process by inhibiting the NEDD8 activating enzyme, NAE, within the murine cardiac tissue subsequent to doxorubicin treatment.This intervention resulted in the suppression of NEDD8 protein expression, reduction in neddylation activity, and consequential manifestation of cardioprotective effects.Collectively, our findings posit MLN4924 as a potential therapeutic avenue for mitigating doxorubicin-induced cardiotoxicity by attenuating heightened neddylation activity through NAE inhibition, thereby offering a viable and promising treatment modality for afflicted patients.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Podocyte-Specific Deletion of MCP-1 Fails to Protect against Angiotensin II- or Adriamycin-Induced Glomerular Disease. (Pubmed Central) - May 11, 2024
After 28 days, there were no between-group differences in survival, change in body weight, albuminuria, kidney function, glomerular injury, and tubulointerstitial fibrosis. The lack of protection in the knockout mice suggests that podocyte-specific MCP-1 production is not a major contributor to either Ang II- or Adr-induced glomerular disease, implicating that another cell type is the source of pathogenic MCP-1 production in CKD.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Exploring CDKN1A Upregulation Mechanisms: Insights into Cell Cycle Arrest Induced by NC2603 Curcumin Analog in MCF-7 Breast Cancer Cells. (Pubmed Central) - May 11, 2024
Our findings reveal potent inhibition of cell viability (IC50 = 5.6 ?M) and greater specificity than doxorubicin toward MCF-7 vs. non-cancer HaCaT cells...We hypothesize that the curcumin analog by inducing GADD45A expression and repressing ESR1, triggers the expression of CDKN1A, which in turn downregulates the expression of many important genes of proliferation and the cell cycle. These insights advance our understanding of curcumin analogs' therapeutic potential, highlighting not just their role in treatment, but also the molecular pathways involved in their activity toward breast cancer cells.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: The Potential of the Fibronectin Inhibitor Arg-Gly-Asp-Ser in the Development of Therapies for Glioblastoma. (Pubmed Central) - May 11, 2024
Liposomes encapsulating doxorubicin (DOX) were also included in the hydrogel to kill GBM cells...Importantly, RGDS-functionalized hydrogel incorporating DOX efficiently damaged GBM cells without affecting astrocyte viability, proving its safety. Overall, the results demonstrate the potential of the RGDS-functionalized hydrogel to develop safe and effective GBM treatments.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Activation of the Anaphase Promoting Complex Restores Impaired Mitotic Progression and Chemosensitivity in Multiple Drug-Resistant Human Breast Cancer. (Pubmed Central) - May 11, 2024
Similar to our previous observations in canine MDR lymphoma cells, chemical activation of the APC using Mad2 Inhibitor-1 (M2I-1) in MCF7 MDR cells enhanced APC substrate degradation and resensitized MDR cells in vitro to the cytotoxic effects of the alkylating chemotherapeutic agent, doxorubicin (DOX)...In our PDX model, mice growing a clinically MDR human triple-negative breast cancer tumor show significantly reduced tumor growth when treated with M2I-1, with evidence of increased DNA damage and apoptosis. Thus, our results strongly support the hypothesis that APC impairment is a driver of aggressive tumor development and that targeting the APC for activation has the potential for meaningful clinical benefits in treating recurrent cases of MDR malignancy.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal: Anticancer Activity of Encapsulated Pearl Millet Polyphenol-Rich Extract against Proliferating and Non-Proliferating Breast Cancer Cells In Vitro. (Pubmed Central) - May 11, 2024
Furthermore, diverse responses to the stimulation with encapsulated polyphenolic extract in senescent breast cancer cells were observed, as in the encapsulated polyphenolic extract-treated non-proliferating AU565 cells, the autophagic pathway, here cytotoxic autophagy, was also induced, as judged by elevated levels of beclin-1 and LC3b. We show for the first time the anti-breast cancer activity of encapsulated polyphenolic extract of pearl millet and postulate that microencapsulation may be a useful approach for potentiating the anticancer effects of phytochemicals with limited bioavailability.
- |||||||||| Review, Journal, Pan tumor: Dissecting the Puzzling Roles of FAM46C: A Multifaceted Pan-Cancer Tumour Suppressor with Increasing Clinical Relevance. (Pubmed Central) - May 11, 2024
Accordingly, FAM46C was recently proposed to function as a pan-cancer prognostic marker, bringing FAM46C under the spotlight and attracting growing interest from the scientific community in the pathways modulated by FAM46C and in its mechanistic activity. Here, we will provide the first comprehensive review regarding FAM46C by covering (1) the intracellular pathways regulated by FAM46C, namely the MAPK/ERK, PI3K/AKT, ?-catenin and TGF-?/SMAD pathways; (2) the models regarding its mode of action, specifically the poly(A) polymerase, intracellular trafficking modulator and inhibitor of centriole duplication models, focusing on connections and interdependencies; (3) the regulation of FAM46C expression in different environments by interferons, IL-4, TLR engagement or transcriptional modulators; and, lastly, (4) how FAM46C expression levels associate with increased/decreased tumour cell sensitivity to anticancer agents, such as bortezomib, dexamethasone, lenalidomide, pomalidomide, doxorubicin, melphalan, SK1-I, docetaxel and norcantharidin.
- |||||||||| cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal, Tumor cell: Chemotherapy-induced PTEN-L secretion promotes the selection of PTEN-deficient tumor cells. (Pubmed Central) - May 11, 2024
Here, we will provide the first comprehensive review regarding FAM46C by covering (1) the intracellular pathways regulated by FAM46C, namely the MAPK/ERK, PI3K/AKT, ?-catenin and TGF-?/SMAD pathways; (2) the models regarding its mode of action, specifically the poly(A) polymerase, intracellular trafficking modulator and inhibitor of centriole duplication models, focusing on connections and interdependencies; (3) the regulation of FAM46C expression in different environments by interferons, IL-4, TLR engagement or transcriptional modulators; and, lastly, (4) how FAM46C expression levels associate with increased/decreased tumour cell sensitivity to anticancer agents, such as bortezomib, dexamethasone, lenalidomide, pomalidomide, doxorubicin, melphalan, SK1-I, docetaxel and norcantharidin. In summary, PTEN-L was identified as a potent inducer of dormancy in PTEN-deficient tumor cells, which increased their efficient selection within the tumor microenvironment.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Combination treatment with PD1/PDL-1 inhibitors for sarcomas: state of the art, next questions. (Pubmed Central) - May 10, 2024
Even when direct comparisons between PD1/PDL-1 inhibitor-based combinations and single agents have not been performed yet in sarcoma, some combinations appear promising. Studies controlling heterogeneity by biomarker or histotype selection contribute to an increase in efficacy or knowledge crucial for future comparative trials.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Combination of ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry and network pharmacology to reveal the key effective compounds and mechanism of Shengxian decoction for ameliorating doxorubicin cardiotoxicity. (Pubmed Central) - May 10, 2024
Network pharmacology and molecular docking experiments indicated that timosaponin B-II, timosaponin A-III, gitogenin, and 7,8-didehydrocimigenol were recognized as the key effective compounds to exert effects against doxorubicin cardiotoxicity by acting on targets such as caspase 3, cyclin-dependent kinase 1, cyclin-dependent kinase 4, receptor tyrosine-protein kinase erbB-2, and mitogen-activated protein kinase 1 in p53 and phosphatidylinositol 3-kinase-Akt signaling pathways. This study developed the understanding of the composition of Shengxian decoction for the treatment of doxorubicin cardiotoxicity, as well as a feasible strategy to elucidate the effective constituents in traditional Chinese medicines.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Mechano-induced cell metabolism disrupts the oxidative stress homeostasis of SAOS-2 osteosarcoma cells. (Pubmed Central) - May 10, 2024
Interestingly, the cyclic applied strain could induce a cytotoxic sensitization (to the doxorubicin-induced cell death), suggesting that mechanical signals are integral regulators of cell cytoprotection. Hence, focusing on the mechanosensitive system as a therapeutic approach could potentially result in more effective treatments for osteosarcoma in the future.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: RNA sequencing of formalin fixed paraffin-embedded heart tissue provides transcriptomic information about chemotherapy-induced cardiotoxicity. (Pubmed Central) - May 9, 2024
Chemotherapeutics, such as doxorubicin (DOX) may cause heart injury, but the mechanisms of these side effects of DOX are not well understood...However, DOX-induced differentially expressed genes in FFPE were related to molecular mechanisms of DOX-induced cardiotoxicity, such as inflammation, calcium binding, endothelial dysfunction, senescence, and cardiac hypertrophy signaling. Our data suggest that, despite the limitations, RNA sequencing of archival FFPE heart tissue supports utilizing FFPE tissues from retrospective studies on cardiovascular disorders, including DOX-induced cardiotoxicity.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: DNA nanodevice as a multi-module co-delivery platform for combination cancer immunotherapy. (Pubmed Central) - May 9, 2024
The doxorubicin (Dox) component induced immunogenic cell death (ICD) in tumor cells and enhanced phagocytosis of antigen-presenting cells (APCs)...The nanodevice promoted the infiltration of CD8+ and CD4+ cells into the tumor and generated a highly inflamed TME, thereby enhancing the effectiveness of cancer immunotherapy. Our research results indicate that the nanodevice we constructed can effectively inhibit tumor growth and prevent lung metastasis without obvious systemic toxicity, providing a promising strategy for cancer combination treatment.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: A minimalist cancer cell membrane-shielded biomimetic nanoparticle for nasopharyngeal carcinoma active-targeting therapy. (Pubmed Central) - May 9, 2024
Chemotherapeutant model drug doxorubicin (DOX) was loaded in polyamidoamine (PAMAM) dendrimer...Further in vivo results confirmed that this biomimetic nanoplatform had extended circulation and remarkable tumor-targeting capability, and the PDC NPs effectively suppressed the progression of CNE-2 tumors by systemic administration. This CCM-shielded biomimetic NP displayed a minimalist paradigm nanoplatform for precise NPC therapy, and the strategy of CCM-shielded biomimetic drug delivery system (DDS) has great potential for extensive cancer active-targeting therapy.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Inhibition of PRMT5-mediated regulation of DKK1 sensitizes colorectal cancer cells to chemotherapy. (Pubmed Central) - May 9, 2024
Knockdown of DKK1 or treatment with the PRMT5 inhibitor CMP5 in combination with doxorubicin yielded a synergistic anti-tumor effect in KRAS mutant, but not KRAS wild-type, CRC cells. These findings suggest that PRMT5 regulates DKK1 expression in CRC and that inhibition of PRMT5 modulates DKK1 expression in such a way that reduces CRC cell growth.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Drug-Loaded Bacillus Calmette-Gu (Pubmed Central) - May 9, 2024
Therefore, it is adopted the "biotin-streptavidin strategy" to doxorubicin (DOX)-encapsulated nanoparticles within live BCG bacteria (DOX@BCG) to improve treatment outcomes...DOX@BCG effectively inhibited cancer progression and prolonged the survival of rats/mice with orthotopic bladder cancer owing to synergism between BCG-immunotherapy, DOX-chemotherapy, and DOX-induced immunogenic tumor cell death; furthermore, it exhibited improved tolerance and biosafety, and established anti-tumor immunity in the tumor microenvironment. Therefore, our drug-loaded live BCG bacterial delivery system holds considerable potential for clinical translation in the intravesical treatment of bladder cancer.
- |||||||||| ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Long-term safety of hypofractionated RT combined with AI in marginally resectable sarcomas () - May 8, 2024 - Abstract #ESTRO2024ESRTO_55;
Although preoperative radiotherapy is usually associated with a greater risk of wound complications than postoperative radiotherapy, early radiotherapy with a 6 to 8 weeks gap to surgery presents an acceptable ratio of surgery-related adverse events despite hypofractionation, combination with chemotherapy and the large tumor size in case of marginally resectable sarcomas. Moreover, the radiotherapy-related late toxicity of such a regimen seems to be not higher than in conventionally fractionated regimens.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: A Synergistic Chemoimmunotherapy System Leveraging PD-L1 Blocking and Bioorthogonal Prodrug Activation. (Pubmed Central) - May 8, 2024
We propose an anti-tumor chemoimmunotherapy system comprising bioorthogonal reaction-ready group tetrazine (TZ) modified with an anti-PD-L1 antibody (?PD-L1TZ) and TZ-activatable prodrug vinyl ether-doxorubicin (DOX-VE) for self-reinforced anti-tumor chemoimmunotherapy...Therefore, the system significantly enhances ?PD-L1 tumor accumulation and prodrug activation and induces a robust immunological memory effect to prevent tumor recurrence and metastasis. Thus, a feasible chemoimmunotherapy combination regimen is presented.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Receptor Ligand-Free Mesoporous Silica Nanoparticles: A Streamlined Strategy for Targeted Drug Delivery across the Blood-Brain Barrier. (Pubmed Central) - May 8, 2024
Importantly, DOX@RMSN25-PEG-TA, our MSN loaded with doxorubicin (DOX), harnessed the enhanced permeability and retention (EPR) effect to achieve a 6-fold increase in brain accumulation compared to free DOX...Advanced LC-MS/MS investigations unveiled a distinctive protein corona surrounding RMSN25-PEG-TA, suggesting proteins such as apolipoprotein E and albumin could play pivotal roles in enabling its BBB penetration. Our results underscore the potential of ligand-free MSNs in treating brain tumors, which supports the development of future drug-nanoparticle design paradigms.
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
PET-guided treatment with BrECADD vs. BEACOPP for advanced stage Hodgkin Lymphoma: Results from the Phase III GHSG HD21 trial (Exhibit Hall D - Science Pavilion (Convention Center); Screen 24; In-Person Only) - May 8, 2024 - Abstract #SNMMI2024SNMMI_1372;
P3
The experimental arm received the BrECADD combination regimen of immunotherapy (Brentuximab vedotin) and chemotherapy (etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone). The standard of care (SOC) arm was treated with eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procar
- |||||||||| Istodax (romidepsin) / Astellas, BMS
Journal: Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial. (Pubmed Central) - May 7, 2024
P3
Within the limits of highly heterogeneous second-line treatments, no specific regimen seemed to provide superior disease control. However, a potential benefit was observed with brentuximab vedotin in association with chemotherapy even after excluding anaplastic large-cell lymphoma subtype or after adjusting for histology and international prognostic index in a multivariate model (HR for PFS, 0.431 [95% CI, 0.238 to 0.779]; P = .005).
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Beneficial Effects of Oral Carbon Monoxide on Doxorubicin-Induced Cardiotoxicity. (Pubmed Central) - May 7, 2024
However, a potential benefit was observed with brentuximab vedotin in association with chemotherapy even after excluding anaplastic large-cell lymphoma subtype or after adjusting for histology and international prognostic index in a multivariate model (HR for PFS, 0.431 [95% CI, 0.238 to 0.779]; P = .005). These findings strongly support using HBI-002 as a cardioprotective agent that maintains the therapeutic benefits of doxorubicin cancer treatment while mitigating cardiac damage.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Diversity Oriented Synthesis of Novel Xanthones Reveal Potent Doxorubicin-Inspired Analogs. (Pubmed Central) - May 7, 2024
Subsequent Suzuki coupling of either halide enabled access to phenyl- and chloro-bearing xanthones, which may be functionalized at four out of five non-hydroxylated positions. Antiproliferative assays against breast cancer cell lines revealed potent activities of some of these simplified analogs that are in the range of pharmaceutically used anticancer drug doxorubicin.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: A Unique Approach: Biomimetic Graphdiyne-Based Nanoplatform to Treat Prostate Cancer by Combining Cuproptosis and Enhanced Chemodynamic Therapy. (Pubmed Central) - May 7, 2024
We developed a nanoplatform to target prostate cancer cells based on graphdiyne (GDY) and a copper-based metal-organic framework (GDY-CuMOF), that carries the chemotherapy drug doxorubicin (DOX) for cancer treatment...In addition, DCM@GDY-CuMOF@DOX effectively suppresses tumor growth in vivo without causing any apparent side effects. The constructed DCM@GDY-CuMOF@DOX nanoplatform integrates tumor targeting, drug-responsive release and combination with cuproptosis and chemodynamic therapy, offering insights for further biomedical research on efficient PCa treatment.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Green Synthesis and Characterization of Silver Nanoparticles Using Moringa Peregrina and Their Toxicity on MCF-7 and Caco-2 Human Cancer Cells. (Pubmed Central) - May 7, 2024
The constructed DCM@GDY-CuMOF@DOX nanoplatform integrates tumor targeting, drug-responsive release and combination with cuproptosis and chemodynamic therapy, offering insights for further biomedical research on efficient PCa treatment. Furthermore, the anticancer potential of the nanoparticles against MCF-7 and Caco-2 in comparison with the standard Doxorubicin revealed that the silver nanoparticles produced significant toxic effects against the studied cancer cell lines with the IC50 values of 41.59 (Caco-2) and 26.93 (MCF-7)
- |||||||||| Rituxan (rituximab) / Roche
Coexistent Localized Primary Renal Lymphoma within Renal Cell Carcinoma in the Native Kidney of a Kidney Transplant Recipient- A Case Report (Poster Hall, Exhibit Hall A, Level 2) - May 6, 2024 - Abstract #ATC2024ATC_1578;
Also, renal involvement in lymphoma is often seen in advanced stages.* We report a tumor comprising RCC and localized primary renal diffuse large B-cell lymphoma (DLBCL) in the native kidney of a 53-year-old kidney transplant recipient after fifteen years of transplant.* End-stage kidney disease was from biopsy-proven chronic interstitial inflammation and advanced glomerulosclerosis in our patient, who had stable renal allograft function on tacrolimus, mycophenolate mofetil (MMF), and prednisolone...He was treated with three cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) as adjuvant therapy...MMF was withheld during chemotherapy, and he continued to be on tacrolimus and prednisone. Our patient reflects the importance of histopathology in incidentally detected renal masses and presents challenges that arise in cases with two different tumors within the same site, especially in an immunosuppressed individual at risk of relapse.
|
